Table 1.

Characteristics	Bevacizumab/Erlotinib (n 35*)	Good	Poor
Sex (%)
Male	14 (40)	11 (42)	3 (37.5)
Female	21 (60)	15 (58)	5 (62.5)
Age, y
Median	59	58	63
Range	36-72	36-72	49-72
Stage
IIIB	6	5	0
VI	27	19	8
Recurrent
RECIST (%)
Partial Response	8	8	0
Stable Disease	21	14	6
< 16 weeks	11	8	5
> 16 weeks	10	6	1
Progressive Disease	6	4	2

^*Stage was not available for 2 of the patients classified as “Good”